Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
Thrombolysis for acute ischemic stroke
TL;DR: Benefit from intravenous thrombolysis when initiated up to 4.5 hours after symptom onset is demonstrated, and pooled analysis of all trials indicates that the sooner that alteplase is given, the greater is the benefit.
Early Versus Late Assessment of Stroke Outcome
TL;DR: The natural history of outcomes after stroke, especially among patients with initially severe stroke, is looked at, to see when recovery typically reaches its plateau at the group level.
Trends in Door-to-Thrombolysis Time in the Safe Implementation of Stroke Thrombolysis Registry: Effect of Center Volume and Duration of Registry Membership
Daniel Strbian,Niaz Ahmed,Nils Wahlgren,Kennedy R. Lees,Danilo Toni,Christine Roffe,Ida L. Surakka,Turgut Tatlisumak +7 more
TL;DR: In this paper, the authors analyzed the trends of door-to-needle times (DNTs) in the Safe Implementation of Thrombolysis in Stroke registry between 2003 and 2011.
Patient outcomes in historical comparators compared with randomised-controlled trials
TL;DR: The beneficial effects of decompressive hemicraniectomy on survival were not confirmed using a historical comparator dataset, and patients identified from Virtual International Stroke Trials Archive may not have been truly representative of patients with malignant middle cerebral artery infarction.
Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study
Nils Wahlgren,Niaz Ahmed,Antoni Dávalos,Werner Hacke,Mónica Millán,Keith W. Muir,Risto O. Roine,Danilo Toni,Kennedy R. Lees +8 more
TL;DR: Alteplase remains safe when given at 3-4.5 h after ischaemic stroke, offering an opportunity for patients who cannot be treated within the standard 3-h timeframe.